Media Coverage
Back to Media CoverageFast-growing Cambridge biotech Sigilon inks $63M diabetes deal with Eli Lilly
The startup is developing what it calls “living therapeutics” — drugs based on engineered cells that can fight a range of disorders when implanted in the body.